Sexton, BioSpherix collaborate to support cell & gene therapy needs

News

FacebookGoogleLinkedInTwitter

25 June, 2020   News

---
This article was originally published by The Science Advisory Board staff writers on the digital media scienceboard.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes.
---

Sexton Biotechnologies is partnering with BioSpherix Medical on the final steps of downstream bioprocessing, fill-finish.

Sexton's off-the-shelf fill system, the Sexton Biotechnologies AF-500, will be combined with BioSpherix' Cytocentric isolator technology to allow for rapid process development and implementation of good manufacturing practice fill-finish.

With the AF-500, systems are ready to ship so developers can immediately begin process development of small volume fill and finish with the equipment they plan to use at clinical scale. Adding BioSpherix to the mix gives the technology the ability to operate within a fully closed environment along with the ability to control temperatures to limit risks during cryopreservation, the firms said.

---
Keep up to date on Innoget's initiative to beat Covid-19 by following the dedicated channel where new innovation needs, novel technologies, news, and events are posted daily.

Other News

NIH researchers investigate virulence of SARS-CoV-2 virus

  • 25 June, 2020

--- This article was originally published by Samantha Black, PhD, The Science Advisory Board staff writer on the digital media scienceboard.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- What makes the SARS-CoV-2 virus so virulent? Researchers from the U.S. National Institutes of Health (NIH) analyzed the genomics of the virus -- and compar...

Read more about this

Ideaya and GSK partner on synthetic lethality programs

  • 25 June, 2020

--- This article was originally published by The Science Advisory Board staff writers on the digital media scienceboard.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- Ideaya Biosciences and GlaxoSmithKline (GSK) have formed a strategic partnership in the emerging oncology field of synthetic lethality. Synthetic lethality occurs when the combi...

Read more about this

Lilly begins phase III trial for COVID-19 therapy

  • 19 June, 2020

--- This article was originally published by The Science Advisory Board staff writers on the digital media scienceboard.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- Eli Lilly has enrolled patients in a phase III study to evaluate the efficacy and safety of baricitinib in hospitalized adults with COVID-19. Baricitinib, marketed by the compan...

Read more about this


Find More News